Viemed Healthcare (NASDAQ:VMD) Research Coverage Started at Barrington Research

Barrington Research began coverage on shares of Viemed Healthcare (NASDAQ:VMD) in a report published on Monday, Marketbeat.com reports. The brokerage issued an outperform rating and a $14.00 price objective on the stock.

A number of other research analysts also recently issued reports on VMD. Wall Street Zen downgraded shares of Viemed Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 15th. Weiss Ratings cut shares of Viemed Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, August 17th. Finally, Freedom Capital lowered shares of Viemed Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $14.00.

Viemed Healthcare Price Performance

Shares of VMD stock opened at $9.33 on Monday. The firm has a market cap of $355.38 million, a P/E ratio of 25.92, a P/E/G ratio of 2.25 and a beta of 1.10. Viemed Healthcare has a fifty-two week low of $6.05 and a fifty-two week high of $12.61. The business’s 50 day moving average price is $10.90 and its 200-day moving average price is $9.89. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.02 and a current ratio of 1.13.

Viemed Healthcare (NASDAQ:VMD) last posted its earnings results on Monday, August 3rd. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.05). The business had revenue of $78.10 million for the quarter, compared to analysts’ expectations of $78.00 million. Viemed Healthcare had a net margin of 4.81% and a return on equity of 10.16%. On average, equities research analysts anticipate that Viemed Healthcare will post 0.41 earnings per share for the current year.

Insider Buying and Selling

In other news, insider William Frazier sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $11.72, for a total value of $117,200.00. Following the completion of the transaction, the insider owned 73,214 shares in the company, valued at $858,068.08. This trade represents a 12.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Timothy Smokoff sold 20,000 shares of Viemed Healthcare stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $11.50, for a total value of $230,000.00. Following the sale, the director owned 75,518 shares in the company, valued at $868,457. This represents a 20.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 20.60% of the company’s stock.

Institutional Trading of Viemed Healthcare

A number of hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC boosted its position in shares of Viemed Healthcare by 0.3% during the first quarter. Renaissance Technologies LLC now owns 442,200 shares of the company’s stock valued at $4,073,000 after buying an additional 1,400 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Viemed Healthcare by 2.2% during the 1st quarter. Bank of New York Mellon Corp now owns 81,326 shares of the company’s stock valued at $749,000 after acquiring an additional 1,773 shares during the period. Martingale Asset Management L P boosted its holdings in shares of Viemed Healthcare by 6.0% during the 4th quarter. Martingale Asset Management L P now owns 42,483 shares of the company’s stock valued at $316,000 after acquiring an additional 2,399 shares during the last quarter. Invesco Ltd. grew its stake in shares of Viemed Healthcare by 17.1% in the fourth quarter. Invesco Ltd. now owns 21,773 shares of the company’s stock worth $162,000 after acquiring an additional 3,173 shares during the period. Finally, State of Alaska Department of Revenue purchased a new position in shares of Viemed Healthcare during the fourth quarter valued at approximately $25,000. Institutional investors own 74.24% of the company’s stock.

Viemed Healthcare Company Profile

Viemed Healthcare, Inc (NASDAQ: VMD) is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.

Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.